Laboratorio Reig Jofre SA
MAD:RJF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Laboratorio Reig Jofre SA
Cash from Operating Activities
Laboratorio Reig Jofre SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Cash from Operating Activities
€1.5m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Almirall SA
MAD:ALM
|
Cash from Operating Activities
€174.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Cash from Operating Activities
€187.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
Cash from Operating Activities
€78.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
Cash from Operating Activities
€7.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratorio Reig Jofre SA
Glance View
Laboratorio Reig Jofre SA engages in the research, development, manufacture, and trade of pharmaceutical drugs. The company is headquartered in Sant Joan Despi, Barcelona and currently employs 1,152 full-time employees. The company went IPO on 2006-11-07. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The firm also provides nutritional cosmetics, and food supplements, among others. The company operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
See Also
What is Laboratorio Reig Jofre SA's Cash from Operating Activities?
Cash from Operating Activities
1.5m
EUR
Based on the financial report for Dec 31, 2025, Laboratorio Reig Jofre SA's Cash from Operating Activities amounts to 1.5m EUR.
What is Laboratorio Reig Jofre SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-42%
Over the last year, the Cash from Operating Activities growth was -95%. The average annual Cash from Operating Activities growth rates for Laboratorio Reig Jofre SA have been -55% over the past three years , -42% over the past five years .
